Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

/DISREGARD RELEASE: XRP Healthcare/

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment...

Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating…

Addressing this situation, the first precision analgesics company, EptivA Therapeutics, partnering with digital technology experts Infopoly Ltd., has developed Pain Cloud®. Addressing this situation, the first precision analgesics company,EptivA Therapeutics, partnering with digital technology experts Infopoly Ltd., has developedPain Cloud®. Pain Cloud is an in-silico method, based on network biology principles, linking open access 'large-data' for unbiased 'omic' enrichment withPain...

Anbogen Therapeutics Announces Completion of A+ Round Financing to Advance…

Given these promising results, Anbogen decided to proceed with the A+ round of financing to secure the necessary funds for ABT-301's clinical trial, without impacting the ongoing Phase II development of ABT-101. Given these promising results, Anbogen decided to proceed with the A+ round of financing to secure the necessary funds for ABT-301's clinical trial, without impacting the ongoing Phase II development of ABT-101. Leveraging ABT-301's compelling immunomodulatory and synergistic...

/DISREGARD RELEASE: XRP Healthcare/

Adoption of MIS Approaches to Broaden Scope for Global Dental Laser Market to…

Growing educational campaigns to make healthcare professionals aware of the product and their advanced technology. Advancements such as lasers which are employed for repairing tooth porosity, welding implants, fixing broken clasps, and Dental Lasers. For instance, Er:YAG lasers are now used as an alternative to acid etching of enamel. Growing educational campaigns to make healthcare professionals aware of the product and their advanced technology. Advancements such as lasers which are…

Photoacoustic Imaging Market: Reaching USD 105 Million by 2029 - Drivers…

Browse in-depth TOC on "Photoacoustic Imaging Market" Browse in-depth TOC on "Photoacoustic Imaging Market" 121 - Tables47 - Figures 171 - Pages Competitive Landscape and Key Players The photoacoustic imaging market is characterized by a competitive landscape with various established and emerging players. Key stakeholders as of 2023 include Advantest Corporation, Cyberdyne, Inc., Fujifilm Corporation, IllumiSonics Inc., iThera Medical Gmbh, Kibero, Opotel LLC, TomoWave...

DC Torque Tool Market worth $4.4 billion by 2029 - Exclusive Report by…

Browse in-depth TOC on "DC Torque Tool Market" 200 – Tables71 – Figures227 – Pages Browse in-depth TOC on "DC Torque Tool Market"200 – Tables 71 – Figures 227 – Pages DC Torque Tool Market Report Scope: The handheld tools segment is to grow with a higher CAGR during the forecast period. The DC torque tool have been segmented into two tool types, handheld tools and fixtured tools. Handheld tools are preferred over fixtured tools due to portability, handheld tools can be...

Soft Tissue Repair Market Size to Worth USD 12.78 Billion by 2034 | With 5.6%…

Because of the increasing aging population, demand for orthopedic procedures is increasing at a significant pace, offering lucrative prospects for soft tissue repair solution providers. Chronic conditions like diabetes-related gangrene, osteoarthritis, and peripheral vascular disease are boosting the demand for orthopedic procedures, including amputations. Consequently, there is a surge in overall sales within the soft tissue repair market. Because of the increasing aging population, demand…

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 01 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…

Buyback of Class B shares in Essity during week 26, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All...

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 1 JULY 2024 at 15:15 EEST Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate CancerOrion Corporation (“Orion”) and MSD (Merck & Co., Inc., Rahway, NJ, USA) today announced that notice has been provided of the mutual exercise of an option to...

Inside information: Orion upgrades full-year outlook for 2024

ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 1 JULY 2024 at 15:15 EEST Inside information: Orion upgrades full-year outlook for 2024Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion and MSD (Merck & Co., Inc., Rahway, NJ, USA) have exercised the option to convert the co-development and co-commercialisation agreement with MSD regarding opevesostat (MK-5684/ODM-208), an investigational...

2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's…

During the forum, Kexing Biopharm warmly welcomed and sincerely thanked the attendees from various backgrounds who had traveled from afar. In addition, they provided a comprehensive introduction to the Company's internationalization strategy and plans for the future. Kexing Biopharm emphasized its commitment to leveraging its overseas commercial platform to deliver high-quality products and comprehensive medication solutions for global patients. It specifically mentioned the successful…

Ping An Co-CEO Michael Guo at "Summer Davos": Low Public Awareness of Financial…

China is aging before becoming rich, Mr. Guo said. When China entered the phase of an aging society in 1999, the GDP per capita was only US$1,000. In comparison, when developed countries in Europe and the US encountered aging populations, their GDP per capita was approximately US$10,000, so they had stronger financial capacity to support senior care. Today, the challenge in China is that retirement replacement ratio is low and whilst there is lack of awareness of importance of financial planning…

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~ ~ Genezen to manufacture global commercial supply of HEMGENIX ®and support uniQure's pipeline programs as a preferred customer ~ ~ uniQure to reduce cash burn by $40 million per year and receive total consideration of $25 million ~~ uniQure's comprehensive review of operations and options to reduce expenses is ongoing and...

Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

Mr. Oliveira is an accomplished biopharmaceutical industry executive with nearly 25 years of commercial experience, building high-performing teams, and launching multiple successful pharmaceutical products “As we continue to advance multiple mid- to late-stage clinical development programs, we are thrilled to welcome Orlando to the Zenas leadership team,” said Joe Farmer, President and Chief Operating Officer. “His expertise and track record of building and leading high performing...

ALLATRA President Discussed Climate Change with Pope Francis

Among the invited guests were Dr. A. Egon Cholakian, a National Security Expert, Washington D.C. Governmental Affairs Advisor to the ALLATRA International Public Movement, CAPP Foundation member; and Maryna Ovtsynova, President of the ALLATRA International Public Movement. Among the invited guests wereDr. A.Egon Cholakian , a National Security Expert,Washington D.C.Governmental Affairs Advisor to the ALLATRA International Public Movement, CAPP Foundation member; and Maryna...

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows: Strong preliminary revenue growth with total revenues for the second quarter between $196 - $201 million. Preliminary total revenues for the first six months are $233 - $238 million, an approximately...

US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems

Press release, Helsinki, 1 July 2024 at 11:30 AM (EEST) US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received an order and delivered two new NBS 6 systems to a private clinic customer in the United States. The customer is an experienced Nexstim system user that is now upgrading its existing systems at two clinic locations.Nexstim launched NBS 6, a new generation nTMS system, in 2023...

Medsenic, BioSenic's subsidiary, signed a new set of licensing and…

Alvotech Issues New Shares to Holders of Convertible Bonds

Oncolytic Viruses: Unlocking a New Era in Cancer Immunotherapy | DelveInsight

/DISREGARD RELEASE: XRP Healthcare/

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Pain Cloud® Launch: A Collaboration between EptivA and Infopoly Ltd., creating…

Anbogen Therapeutics Announces Completion of A+ Round Financing to Advance…

/DISREGARD RELEASE: XRP Healthcare/

/DISREGARD RELEASE: XRP Healthcare/

Adoption of MIS Approaches to Broaden Scope for Global Dental Laser Market to…

Photoacoustic Imaging Market: Reaching USD 105 Million by 2029 - Drivers…

DC Torque Tool Market worth $4.4 billion by 2029 - Exclusive Report by…

Soft Tissue Repair Market Size to Worth USD 12.78 Billion by 2034 | With 5.6%…

Novo Nordisk A/S - share repurchase programme

Buyback of Class B shares in Essity during week 26, 2024

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing…

Inside information: Orion upgrades full-year outlook for 2024

2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's…

Ping An Co-CEO Michael Guo at "Summer Davos": Low Public Awareness of Financial…

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

ALLATRA President Discussed Climate Change with Pope Francis

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the…

US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems